Emtricitabine (FTC) — Competitive Intelligence Brief

Emtricitabine (FTC) (Emtricitabine (FTC)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitor (NRTI). Area: Infectious Disease / Virology.

phase 3 Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Emtricitabine (FTC) (Emtricitabine (FTC)) — National University Hospital, Singapore. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV reverse transcriptase, preventing viral RNA from being converted into DNA and integrated into host cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Emtricitabine (FTC) TARGET	Emtricitabine (FTC)	National University Hospital, Singapore	phase 3	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase
Didanosine (enteric-coated)	Didanosine (enteric-coated)	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase
didanosine + lamivudine + efavirenz	didanosine + lamivudine + efavirenz	Clinical Trial Agency of HIV Study Group	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase
ELV/COBI/FTC/TAF	ELV/COBI/FTC/TAF	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination therapy (integrase inhibitor + NRTI + NtRTI + pharmacokinetic booster)	HIV integrase, HIV reverse transcriptase
Dolutegravir/Lamivudine	Dolutegravir/Lamivudine	Saint Michael's Medical Center	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase
Combivir+Kaletra	Combivir+Kaletra	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + protease inhibitor)	HIV reverse transcriptase and HIV protease
DTG/3TC/ABC + ELV/COBI/FTC/TAF	DTG/3TC/ABC + ELV/COBI/FTC/TAF	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitor (NRTI) class)

1. French National Agency for Research on AIDS and Viral Hepatitis · 3 drugs in this class
2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
3. ViiV Healthcare · 2 drugs in this class
4. Nanfang Hospital, Southern Medical University · 2 drugs in this class
5. Asan Medical Center · 1 drug in this class
6. Dong-A ST Co., Ltd. · 1 drug in this class
7. Bristol-Myers Squibb · 1 drug in this class
8. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
9. Fu-Sheng Wang · 1 drug in this class
10. Avexa · 1 drug in this class